HYOU1 Promotes Cell Growth and Metastasis Via Activating PI3K/AKT Signaling in Epithelial Ovarian Cancer and Predicts Poor Prognosis
Total Page:16
File Type:pdf, Size:1020Kb
European Review for Medical and Pharmacological Sciences 2019; 23: 4126-4135 HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis X. LI1, N.-X. ZHANG2, H.-Y. YE3, P.-P. SONG3, W. CHANG3, L. CHEN1, Z. WANG1, L. ZHANG1, N.-N. WANG4 1Department of Gynecology, 2Department of Hospital Acquired Infection Control, 3Department of Endocrinology, 4Department of Cadre Health Care; Qingdao Hiser Medical Group, Qingdao, Shandong, China. Abstract. – OBJECTIVE: Hypoxia upregulat- Introduction ed 1 (HYOU1) has been reported to be abnor- mally expressed in different malignancies, es- Ovarian cancer is a leading cause of death pecially in breast cancer. However, the role of among gynecological cancers worldwide, and the HYOU1 in epithelial ovarian cancer (EOC) re- mains largely unclear. This study aimed to ex- fatality rate of ovarian cancer is the highest of plore the expression and function of HYOU1 in all types of gynecological tumors, causing about EOC progression. 140,200 deaths in the world annually1,2. The epi- PATIENTS AND METHODS: HYOU1 levels thelial ovarian cancer (EOC) is a common entity in EOC tissues and cell lines were investigat- accounting for 80 to 90% of ovarian cancer cases3. ed by RT-PCR. The clinical and prognostic The current standard of therapy is the debulking significance of HYOU1 in 127 cases of EOC 4 was analyzed using the Chi-square analysis, surgery combined with chemotherapy . In spite Kaplan-Meier analysis, and the Cox propor- of continuous efforts to improve the therapeutic tional hazards regression model. We have al- response, the prognosis of EOC patients remains so performed multiple cells experiments to poor, with a 5-year survival rate of only 30%5,6. In evaluate the effects of HYOU1 on EOC cell addition, although growing researches have been proliferation, apoptosis, migration, and inva- published in recent years and have contributed sion. The protein levels of associated PI3K/ Akt signaling pathway was detected using to the understanding of the basic and clinical Western blot assay. knowledge, the complex molecular mechanism of RESULTS: We found that the expression lev- EOC is still insufficiently understood7. Thus, it is els of HYOU1 were significantly upregulated necessary to further study the molecular mech- in both EOC tissues and cell lines. A higher anisms involved in EOC carcinogenesis and to expression of HYOU1 was associated with ad- identify the prognostic markers for the design of vanced FIGO stage, LN metastasis, and short- er overall survival. In addition, univariate and the individual therapy, and the targeted treatment multivariate analysis identified high HYOU1 ex- of EOC. Hypoxia upregulated 1 (HYOU1), also pression as an unfavorable prognostic factor known as Grp170 and HSP12A, is encoded by for overall survival. Functional assays revealed this HYOU1 gene and belongs to the heat shock that the inhibition of HYOU1 suppressed the protein 70 family8,9. Up to date, the biological tumor proliferation and colony formation, as function of HYOU1 in cell progress remains well as the migratory and invasive capacity. Fi- nally, when HYOU1 was silenced, the results of largely unclear. Previously, evidence has shown Western blot showed that the levels of p-PI3K, that HYOU1 may be involved in the regulation p-Akt, as well as cell cycle and EMT genes, were of apoptosis and its inhibition is correlated with respectively downregulated. accelerated apoptosis10,11. In addition, there are CONCLUSIONS: Our findings highlighted the cellular experiments which indicate that this gene targeting of HYOU1 as a novel therapeutic ap- has an important cytoprotective role in hypox- proach for the treatment of EOC. ia-induced cellular perturbation. Recently, with Key Words: the development of sequencing technology, the HYOU1, Epithelial ovarian cancer, PI3K/AKT signal- dysregulation of HYOU1 was reported in several ing pathway, Prognosis, Tumorigenesis. tumors, which suggested that HYOU1 may play a 4126 Corresponding Author: Na-Na Wang, MD; e-mail: [email protected] HYOU1 expression in epithelial ovarian cancer functional effect in the development and progres- normal tissue samples were immediately frozen sion of tumors12,13. Zhou et al14 firstly reported that using liquid nitrogen and subsequently stored at HYOU1 was highly expressed in nasopharyngeal -80°C for further use. No patients received any carcinoma and associated with poor prognosis chemotherapy, immunotherapy or radiotherapy of the patient with nasopharyngeal carcinoma, before the surgery. The informed consents were suggesting that HYOU1 may serve as a tumor obtained from all patients. promoter in this disease, although in vitro and in vivo experiments were not been performed. How- Cell Lines and Cell Transfection ever, whether HYOU1 was abnormally expressed We obtained IOSE80 (ovarian epithelial cells) in EOC, as well as its potential biological func- and three EOC cells, HEY, SKOV3, OVCAR-3, tion in the progression of EOC, remains largely from Uban Biotechnology Co., Ltd. (Jiading, unclear. In this study, we analyzed microarray Shanghai, China). The cells were maintained in data from GEO datasets, finding that HYOU1 RPMI 1640 medium (BioSUN, Xuhui, Shang- expression was significantly up-regulated in EOC hai, China) supplemented with fetal bovine serum tissues, which was consistent with the expression (FBS; 10% concentration) and penicillin-strepto- trend of HYOU1 in breast cancer9 and naso- mycin antibiotics solution (1%; HY Stem Cells, pharyngeal carcinoma14. Furthermore, RT-PCR Shapingba, Chongqing, China). For cell trans- assays of clinical samples from our hospital also fection, a LipoFiter 3 transfection reagent (Han- confirmed that HYOU1 was overexpressed in Bio, Jiading, Shanghai, China) was employed to EOC tissues. Given the possibility of HYOU1 as transfect small interfering RNAs (siRNAs) into a potential positive regulator in EOC, we further SKOV3 and OVCAR-3 cells. The siRNAs target- analyzed its prognostic value in EOC patients ing HYOU1 (si-HYOU1-1 and si-HYOU1-2) and and performed a lost-function assay to explore negative control siRNAs (si-NC) were purchased its specific biological function in the progression from ZoonBio Co., Ltd. (Nanjing, Jiangsu, China). of EOC. Finally, we also tried to explore the potential mechanism of HYOU1 involved in the RNA Isolation and Quantitative proliferation and metastasis. Real Time-PCR The total RNA from EOC tissues or cells was extracted using TRIzol reagent, and the quantity Patients and Methods of the RNA was determined by NanoDrop ND- 1000 spectrophotometer (Thermo Fisher Scien- Clinical Specimens tific, Waltham, MA, USA). Then, the cDNA was A total of 127 EOC patients (relevant clini- reverse-transcribed using Fermentas RevertAid cal features were summarized in Table I) were first strand cDNA synthesis kit (Think-far, Haid- enrolled in this research, which was approved ian, Beijing, China). Afterward, qRT-PCR as- by the Ethics Committee of Qingdao Hiser Med- says for HYOU1 determination were conducted ical Group from April 2010 to March 2013. using SYBR Premix Ex Taq real time-PCR kit The EOC specimens and adjacent non-cancerous (TaKaRa, Dalian, Liaoning, China). Glyceralde- Table I. Correlation between HYOU1 expression with clinicopathologic features of EOC. Parameters Category No. HYOU1 expression p-value High Low Age (y) ≤50 63 30 33 0.657 >50 64 33 31 FIGO stage I-II 80 34 46 0.037 III-IV 47 29 18 Differentiation 1/2 72 32 40 0.183 3 55 31 24 Tumor size ≤5 cm 89 45 44 0.384 >5 cm 48 28 20 LN Metastasis No 87 37 50 0.019 Yes 40 26 14 4127 X. Li, N.-X. Zhang, H.-Y. Ye, P.-P. Song, W. Chang, L. Chen, Z. Wang, L. Zhang, N.-N. Wang Table II. Microorganism isolated from patients with PJI. EdU Assays Genes Primer sequences (5’-3’) EdU (5-Ethynyl-2’-deoxyuridine; SolarBio, Tongzhou, Beijing, China) assays were applied HYOU1: Forward GAGGAGGCGAGTCTGTTGG to examine the proliferation of SKOV3 and OV- HYOU1: Reverse GCACTCCAGGTTTGACAATGG CAR-3 cells. In short, after transfection with GAPDH: Forward TGGCCTTCCGTGTTCCTAC HYOU1 siRNAs or negative control siRNAs, GAPDH: Reverse GAGTTGCTGTTGAAGTCGCA the SKOV3, and OVCAR-3 cells were harvested and re-plated in 48 well plates. Forty-eight hours later, the EdU reagent (100 μl per well) was added hyde-3-phosphate dehydrogenase (GAPDH) was into the cells, and the plates were continued to be used as the reference gene. Relative HYOU1 ex- cultured for 2 h. Then, the Phosphate-buffered pression was calculated using the 2−DDCt method. saline (PBS) was used to wash the cells, and the The primers for HYOU1 are listed in Table II. DAPI reagent was added into the cells. After rinsing with PBS twice, a NIB100F fluorescence Western Blot Assays microscope (Micro-Science, Jinan, Shandong, HYOU1 siRNAs-transfected SKOV3 and OV- China) was applied to observe the cellular flu- CAR-3 cells were lysed using RIPA lysis buffer orescence. (SeeBio, Pudong, Shanghai, China), and a BCA assay kit (HuaMaiKe, Changping, Beijing, China) Cell Colony Formation Assays was applied to measure the concentration of pro- For colony formation assays, the SKOV3 and teins. Subsequently, 20 μg proteins (per lane) were OVCAR-3 cells were first transfected with HY- separated by 8-10% sodium salt-polyacrylamide OU1 siRNAs or negative control siRNAs. Then, gel electrophoresis (SDS-PAGE) using a Bio-Rad the treated cells were harvested and re-placed into Western blot apparatus and then, transferred to 6-well plates (500 cells per well). The transfections Millipore polyvinylidene difluoride (PVDF) mem- were re-conducted every 3 days. Two weeks later, branes. Next, non-fat milk (5%) was employed to the cell colonies were stained using 0.2% crystal block the membranes, and sequentially the mem- violet solution (in 20% methanol) and subsequent- branes were probed by primary antibodies target- ly photographed by a NIB100F microscope (Mi- ing GAPDH, vimentin, N-cadherin, phosphorylat- cro-Science, Jinan, Shandong, China). ed-PI3K (p-PI3K), phosphorylated-AKT (p-AKT), PI3K, and AKT for 12 h at 4°C.